D.C. Circuit Upholds FDA Rule On 180-Day Exclusivity
The court delivered its decision against Canadian generic drug maker Apotex Inc. earlier this week, determining that the arguments presented “adequately support FDA's position that an estoppel-based approach to the court decision trigger is ill-advised."
The decision marks the second...
To view the full article, register now.